{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.49","upperLimit":"0.71","value":"0.61"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"97"}],"units":"Participants"}],"description":"27-week overall survival is the probability of patients remaining alive at 27-weeks from study entry estimated using with Kaplan-Meier methods.","dispersionType":"95% Confidence Interval","groups":[{"description":"Thalidomide: Start at 3 mg/kg (rounded to nearest 50 mg), increasing dose weekly by 50 mg as tolerated to 24 mg/kg (max 1,000 mg); Celecoxib: \\< 20 kg at 100 mg; 20-50 kg at 200 mg; \\> 50 kg at 400 mg; Fenofibrate: 90 mg/m2 (max 200 mg); Etoposide: 50 mg/m2; Cyclophosphamide: 2.5 mg/kg (max 100 mg); Patients receive oral etoposide once daily on days 1-21 and 43-63 (weeks 1-3 and 7-9) and oral cyclophosphamide once daily on days 22-42 (weeks 4-6). Patients also receive oral thalidomide once daily, oral celecoxib twice daily, and oral fenofibrate once daily in weeks 1-9. Treatment repeats approximately every 9 weeks for at least 3 courses in the absence of disease progression or unacceptable toxicity. Patients receive alternating etoposide and cyclophosphamide pulses (i.e., etoposide-cyclophosphamide-etoposide during courses 1 and 3 and cyclophosphamide-etoposide-cyclophosphamide during course 2).","id":"OG000","title":"5-drug Metronomic Antiangiogenic Regimen"}],"paramType":"NUMBER","populationDescription":"The analysis dataset is comprised of all treated patients.","timeFrame":"Assessed every 9 weeks on treatment and annually until death or initiation of new therapy, up to 27 weeks.","title":"27-Week Overall Survival","type":"SECONDARY","unitOfMeasure":"Probability"}